Skip to main content
. 2015 Aug 20;6(30):29456–29468. doi: 10.18632/oncotarget.4909

Figure 3. Therapeutic effects of the combined effect with TMZ and Ercc1-siRNA in vivo.

Figure 3

In vivo combined effects of Ercc1#1-, Ercc1#3- or Mgmt-siRNA (4 μg) with TMZ (4.2 mg/kg) on U373 xenografts growth. The combined therapy with TMZ and Ercc1#3 (dash line) provided a significantly stronger reduction of tumor growth than TMZ with a control siRNA (GFP) (*, p < 0.05). The first day of administration was defined as ‘day 0′. The days on which the treatments were administered are indicated by grey (TMZ) and black (siRNA) lines at the bottom of the graphs. Mean tumor volumes +/− SE are shown. 2-tailed Student's T-tests were used to evaluate results significance.